Ocular Therapeutix Schedules June 17 Investor Day to Detail AXPAXLI NDA and Trial Updates
OCUL•Ocular Therapeutix will host an Investor Day in New York City on June 17, 2026 at 2:00 PM ET featuring senior leadership and key ophthalmology experts. Presentations will outline the AXPAXLI wet AMD NDA submission plan, SOL-R and SOL-X trial progress, registrational diabetic retinopathy program updates and commercialization strategy.
1. Event Details
Ocular Therapeutix will host an Investor Day in New York City on June 17, 2026, starting at 2:00 PM ET. The live event will feature senior leadership presentations, roundtable discussions with ophthalmology experts, a live Q&A session and a networking reception for in-person attendees, with virtual access available.
2. AXPAXLI Regulatory Plans
Ocular Therapeutix’s leadership will detail the planned NDA submission timeline for AXPAXLI in wet age-related macular degeneration, outlining key regulatory milestones and expected review pathways.
3. Clinical Trial Updates
The company will provide progress reports on the ongoing SOL-R and SOL-X wet AMD trials, as well as updates on the registrational diabetic retinopathy program for AXPAXLI.
4. Commercialization Strategy
Presenters will discuss the planned commercialization strategy for AXPAXLI in wet AMD, including market positioning, potential pricing frameworks and expected launch sequencing if approved.
